We serve Chemical Name:ethyl 7-amino-5-oxo-1H-pyrazolo[1,5-a]pyrimidine-3-carboxylate CAS:90674-09-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![ethyl 7-amino-5-oxo-1H-pyrazolo[1,5-a]pyrimidine-3-carboxylate](https://a.dearchem.com/CAS2/90674-09-2.png)
Chemical Name:ethyl 7-amino-5-oxo-1H-pyrazolo[1,5-a]pyrimidine-3-carboxylate
CAS.NO:90674-09-2
Synonyms:SS-5030;ethyl 7-amino-5-hydroxy-8-hydropyrazolo[1,5-a]pyrimidine-3-carboxylate;7-amino-5-oxo-4,5-dihydro-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester;ethyl 7-amino-5-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxylate;QC-5384
Molecular Formula:C9H10N4O3
Molecular Weight:222.20100
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.614g/cm3
Index of Refraction:1.71
PSA:102.74000
Exact Mass:222.07500
LogP:0.77500
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like SS-5030 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,QC-5384 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl 7-amino-5-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxylate Use and application,7-amino-5-oxo-4,5-dihydro-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester technical grade,usp/ep/jp grade.
Related News: J&J’s shot generates roughly 8 GBS cases per million vaccinated people, far higher than just a single case reported per million among mRNA recipients, CDC reported. 2-chlorothiophene-3-carbaldehyde manufacturers For Franco Stevanato, tapping public markets will give the company the freedom to keep innovating as it enters the next chapter of its 70-plus-year history. 2-chlorothiophene-3-carbaldehyde suppliers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. 2-chlorothiophene-3-carbaldehyde vendor & factory.
